In Brief: Questran switch revisited

Questran switch revisited: Reconsideration of Bristol-Myers Squibb's cholesterol-lowering drug by the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees scheduled for May 13. At the meeting, BMS is expected to present data requested by the committee during its previous consideration of the switch in October 1995, including results of an "actual use" study to measure consumer compliance with label instructions to see a doctor before starting the drug and during usage. The company's data were considered insufficient to support the switch of Questran powdered cholestyramine resin and Questran Light cholestyramine plus aspartame at the previous meeting ("The Tan Sheet" Oct. 2, 1995, pp. 8-12). The meeting will be held at the Holiday Inn Bethesda, Versailles Ballrooms I & II...